SGLT-2 inhibitors and risk of 59 long-term health conditions, hospitalisation, and mortality
Clicks: 5
ID: 325605
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.2
/100
5 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #55 of 96 articles by views in european journal of endocrinology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is often the first condition on the pathway to patients developing multiple long-term conditions (MLTC). The impact of sodium-glucose cotransporter 2 inhibitors (SGLT-2i), a key T2DM treatment, on hospitalisation and MLTC progression remains uncertain. METHODS: In this comparative effectiveness study, we emulated a target trial using linked primary care, hospital, and mortality records in England (2012-2023). Adults aged ≥40 years with T2DM initiating SGLT-2i or dipeptidyl peptidase-4 inhibitors (DPP-4i) were included (n=364,522). Outcomes included all-cause mortality, first hospitalisation, number of hospitalisations, and incidence of 59 prespecified long-term conditions across 17 organ systems. Weighted Cox proportional hazards and negative binomial regression models were used to estimate adjusted hazard ratios (aHRs) or adjusted mean differences (aMDs), with 95% CIs and Benjamini-Yekutieli correction for multiple testing. FINDINGS: Compared with DPP-4i, SGLT-2i use was associated with lower risks of all-cause mortality (aHR 0.73, 95% CI 0.71-0.75), first hospitalisation (aHR 0.86, 95% CI 0.85-0.87), and number of hospitalisations (aMD -0.36, 95% CI -0.38 to -0.34; all p<0.001). SGLT-2i initiators had reduced risks for 28 conditions, including dementia, cancer, metabolic dysfunction-associated steatotic liver disease, diabetic foot ulcer, epilepsy, and rheumatoid arthritis. Increased risks were observed for four conditions, including candidiasis and diabetic ketoacidosis. INTERPRETATION: SGLT-2i use in T2DM was associated with significant reductions in mortality, hospitalisation, and MLTC burden. The broad protective effects across multiple organ systems highlight the potential of SGLT-2i to offer a holistic therapeutic strategy in the management of diabetes and its multisystem complications.
| Reference Key |
openalex_W7203792698
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jingya Wang, Jennifer Cooper, Eleanor Hathaway, Megha Singh, Lei Su, Krishna Gokhale, Steven Wambua, Francesca L. Crowe, Nicola J. Adderley, G Neil Thomas, Graham Lipkin, Lisa J Hill, Indranil Dasgupta, Wasim Hanif, Punith Kempegowda, Kesavapillai Subramonian, Kar Keung Cheng, Thomas Jackson, Konstantinos A. Toulis, Krishnarajah Nirantharakumar |
| Journal | european journal of endocrinology |
| Year | 2026 |
| DOI |
10.1093/ejendo/lvag156
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.